Department of Microbiology and Parasitology, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
J Antimicrob Chemother. 2019 Feb 1;74(2):407-415. doi: 10.1093/jac/dky438.
The global emergence of Neisseria gonorrhoeae isolates displaying high-level azithromycin resistance is a major concern for the currently recommended azithromycin/ceftriaxone dual therapy. N. gonorrhoeae high-level azithromycin resistance has been associated with an A2059G mutation in 23S rRNA. Here we investigated the specific contribution of this 23S rRNA A2059G mutation to high-level azithromycin resistance and its impact on biological fitness.
A2059G/G2059A alleles were specifically cloned into all four genomic copies of 23S rDNA of an azithromycin-susceptible isolate and a high-level azithromycin-resistant isolate. WT and mutant strains were subsequently investigated for azithromycin susceptibility using the agar dilution method. In addition, their biological fitness was studied by comparative liquid growth in the presence of hydrophobic and amphipathic compounds, by competition assays in a mouse vaginal tract infection model and by competition assays for invasion and intracellular survival.
Azithromycin susceptibility analyses showed that the 23S rRNA A2059G mutation is the only genetic determinant required for N. gonorrhoeae to display the high-level azithromycin resistance phenotype. Further analysis of biological fitness showed that strains containing 2059G outcompeted isogenic strains containing 2059A for colonization in the mouse vaginal tract infection model and for invasion of HeLa cervical epithelial cells. Furthermore, the A2059G mutation enhanced growth in the presence of lithocholic acid or Triton X-100.
Our findings that the 23S rRNA A2059G mutation is sufficient for high-level azithromycin resistance and that this mutation generally enhanced the biological fitness of N. gonorrhoeae have important implications for the currently recommended treatment policies and antimicrobial stewardship programmes.
淋病奈瑟菌分离株对高水平阿奇霉素耐药的全球出现是目前推荐的阿奇霉素/头孢曲松双重疗法的主要关注点。高水平阿奇霉素耐药的淋病奈瑟菌与 23S rRNA 中的 A2059G 突变有关。在这里,我们研究了 23S rRNA A2059G 突变对高水平阿奇霉素耐药的特异性贡献及其对生物学适应性的影响。
将 A2059G/G2059A 等位基因特异性克隆到一个对阿奇霉素敏感的分离株和一个高水平阿奇霉素耐药的分离株的四个基因组拷贝的 23S rDNA 中。随后使用琼脂稀释法研究 WT 和突变株对阿奇霉素的敏感性。此外,通过在存在疏水性和两亲性化合物的情况下进行比较液体生长、在小鼠阴道感染模型中的竞争测定以及在侵袭和细胞内生存方面的竞争测定来研究它们的生物学适应性。
阿奇霉素敏感性分析表明,23S rRNA A2059G 突变是淋病奈瑟菌显示高水平阿奇霉素耐药表型所必需的唯一遗传决定因素。进一步的生物学适应性分析表明,含有 2059G 的菌株在小鼠阴道感染模型中定植和侵袭 HeLa 宫颈上皮细胞方面比含有 2059A 的同基因菌株更具竞争力。此外,A2059G 突变增强了在石胆酸或 Triton X-100 存在下的生长。
我们的研究结果表明,23S rRNA A2059G 突变足以导致高水平阿奇霉素耐药,并且该突变通常增强了淋病奈瑟菌的生物学适应性,这对目前推荐的治疗政策和抗菌药物管理计划具有重要意义。